Aurora Cannabis Reports Strong Q2 Growth Driven By International Medical Marijuana Sales
Canadian medical marijuana giant Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) reported its financial results Wednesday for the second quarter of fiscal 2025, showing revenue of CA$81.1 million ($58.3 million), up from CA$63.1 million in the same period last year.
The company attributed the 29% increase from the prior period to 41% growth in its global medical cannabis business and 21% growth in its plant propagation business, slightly offset by lower quarterly revenue in its consumer cannabis business.
“Our strong quarterly results demonstrate Aurora’s leadership in global medical cannabis and ability to capitalize on opportunities within rapidly growing markets such as Australia, Germany, Poland, and the UK,” stated chairman and chief executive officer Miguel Martin. “International revenue increased 93% to $35 million, exceeding Canadian Medical revenue for the first time, and contributing 57% to total global medical cannabis revenue. The Bevo plant propagation segment also grew a robust 21% during its seasonally lowest quarter, proving the efficacy of our diversified operating model,”
Read Also: Why Weed Aroma Matters: Aurora Cannabis Collaborates In Study On Marijuana Smells
Get Benzinga’s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter